These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 25077423)

  • 1. Vaccination against the M protein of Streptococcus pyogenes prevents death after influenza virus: S. pyogenes super-infection.
    Klonoski JM; Hurtig HR; Juber BA; Schuneman MJ; Bickett TE; Svendsen JM; Burum B; Penfound TA; Sereda G; Dale JB; Chaussee MS; Huber VC
    Vaccine; 2014 Sep; 32(40):5241-9. PubMed ID: 25077423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivated and live, attenuated influenza vaccines protect mice against influenza: Streptococcus pyogenes super-infections.
    Chaussee MS; Sandbulte HR; Schuneman MJ; Depaula FP; Addengast LA; Schlenker EH; Huber VC
    Vaccine; 2011 May; 29(21):3773-81. PubMed ID: 21440037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective immunity induced by an intranasal multivalent vaccine comprising 10 Lactococcus lactis strains expressing highly prevalent M-protein antigens derived from Group A Streptococcus.
    Wozniak A; Scioscia N; García PC; Dale JB; Paillavil BA; Legarraga P; Salazar-Echegarai FJ; Bueno SM; Kalergis AM
    Microbiol Immunol; 2018 Jun; 62(6):395-404. PubMed ID: 29704396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prime-Pull Immunization with a Bivalent M-Protein and Spy-CEP Peptide Vaccine Adjuvanted with CAF®01 Liposomes Induces Both Mucosal and Peripheral Protection from
    Ozberk V; Reynolds S; Huo Y; Calcutt A; Eskandari S; Dooley J; Mills JL; Rasmussen IS; Dietrich J; Pandey M; Good MF
    mBio; 2021 Feb; 12(1):. PubMed ID: 33622722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy targeting the Streptococcus pyogenes M protein or streptolysin O to treat or prevent influenza A superinfection.
    Herrera AL; Van Hove C; Hanson M; Dale JB; Tweten RK; Huber VC; Diel D; Chaussee MS
    PLoS One; 2020; 15(6):e0235139. PubMed ID: 32574205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced protection against Streptococcus pyogenes infection by intranasal vaccination with a dual antigen component M protein/SfbI lipid core peptide vaccine formulation.
    Olive C; Schulze K; Sun HK; Ebensen T; Horváth A; Toth I; Guzman CA
    Vaccine; 2007 Feb; 25(10):1789-97. PubMed ID: 17229503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral immunization of mice with engineered Lactobacillus gasseri NM713 strain expressing Streptococcus pyogenes M6 antigen.
    Mansour NM; Abdelaziz SA
    Microbiol Immunol; 2016 Aug; 60(8):527-32. PubMed ID: 27301486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and microbiological response of mice to intranasal inoculation with Lactococcus lactis expressing Group A Streptococcus antigens, to be used as an anti-streptococcal vaccine.
    García PC; Paillavil BA; Scioscia N; Dale JB; Legarraga P; Salazar-Echegarai FJ; Bueno SM; Kalergis AM; Wozniak A
    Microbiol Immunol; 2018 Nov; 62(11):711-719. PubMed ID: 30357922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes.
    Mannam P; Jones KF; Geller BL
    Infect Immun; 2004 Jun; 72(6):3444-50. PubMed ID: 15155651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combinatorial Synthetic Peptide Vaccine Strategy Protects against Hypervirulent CovR/S Mutant Streptococci.
    Pandey M; Mortensen R; Calcutt A; Powell J; Batzloff MR; Dietrich J; Good MF
    J Immunol; 2016 Apr; 196(8):3364-74. PubMed ID: 26969753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Similar ability of FbaA with M protein to elicit protective immunity against group A streptococcus challenge in mice.
    Ma CQ; Li CH; Wang XR; Zeng RH; Yin XL; Feng HD; Wei L
    Cell Mol Immunol; 2009 Feb; 6(1):73-7. PubMed ID: 19254483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenic mechanisms of invasive group A Streptococcus infections by influenza virus-group A Streptococcus superinfection.
    Okamoto S; Nagase S
    Microbiol Immunol; 2018 Mar; 62(3):141-149. PubMed ID: 29377225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concerns for efficacy of a 30-valent M-protein-based Streptococcus pyogenes vaccine in regions with high rates of rheumatic heart disease.
    Giffard PM; Tong SYC; Holt DC; Ralph AP; Currie BJ
    PLoS Negl Trop Dis; 2019 Jul; 13(7):e0007511. PubMed ID: 31269021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination with formalin-inactivated influenza vaccine protects mice against lethal influenza Streptococcus pyogenes superinfection.
    Okamoto S; Kawabata S; Fujitaka H; Uehira T; Okuno Y; Hamada S
    Vaccine; 2004 Jul; 22(21-22):2887-93. PubMed ID: 15246625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccine Approaches To Protect against Group A Streptococcal Pharyngitis.
    Fischetti VA
    Microbiol Spectr; 2019 May; 7(3):. PubMed ID: 31111819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The quest for GAS vaccine.
    Pandey M; Good MF
    Oncotarget; 2015 Oct; 6(33):34063-4. PubMed ID: 26485764
    [No Abstract]   [Full Text] [Related]  

  • 17. Analysis of the coverage capacity of the StreptInCor candidate vaccine against Streptococcus pyogenes.
    De Amicis KM; Freschi de Barros S; Alencar RE; Postól E; Martins Cde O; Arcuri HA; Goulart C; Kalil J; Guilherme L
    Vaccine; 2014 Jul; 32(32):4104-10. PubMed ID: 23994376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus.
    Olive C; Ho MF; Dyer J; Lincoln D; Barozzi N; Toth I; Good MF
    J Infect Dis; 2006 Jun; 193(12):1666-76. PubMed ID: 16703510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a multicomponent vaccine for Streptococcus pyogenes based on the antigenic targets of IVIG.
    Reglinski M; Lynskey NN; Choi YJ; Edwards RJ; Sriskandan S
    J Infect; 2016 Apr; 72(4):450-9. PubMed ID: 26880087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunity to group a streptococcal M proteins: forging a single-edged sword.
    Madoff LC
    Clin Infect Dis; 2005 Oct; 41(8):1123-4. PubMed ID: 16163630
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.